julijana.stula@baselarea.swiss

We’re excited to welcome Umlaut.bio to our portfolio. Umlaut.bio, a spin-off from EMBL in Heidelberg, is pioneering the development of small molecules inhibiting tRNA modifications…

Basel, February 18th, 2026 - FimmCyte AG (“FimmCyte”), a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research collaboration and…

Basel, Switzerland - February 10, 2026 — BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the…

We are pleased to announce a partnership with Catalent, Inc., a global contract development and manufacturing organization (CDMO) supporting pharmaceutical, biotech and consumer health companies…

Basel, Switzerland - December 16, 2025 — BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has…

Basel, Switzerland - 11 December 2025, Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters…